Active Clinical Research for Hepatocellular, Liver and Lung Cancer

Comprehensive Cancer Centers runs Phase II and Phase III research trials for the following Hepatocellular, liver and lung cancers:

Randomized, Controlled, Open-label, Phase 3, Global Multi- Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations **OPEN TO COHORT B ONLY**
Study#: i3200
Contact Us: For information about this clinical study, Email Us.

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations **COHORT A- CLOSED TO ENROLLMENT; COHORTS B (2 SLOTS REMAINING) AND C (3 SLOTS OPEN)- CONTACT MONITOR FOR SLOT; COHORT D ON HOLD TO ENROLLMENT DUE TO INTERIM ANALYSIS**
Study#: i3211
Contact Us: For information about this clinical study, Email Us.

A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression
Study#: i3280
Contact Us: For information about this clinical study, Email Us.

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing FirstLine Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.
Study#: i3292
Contact Us: For information about this clinical study, Email Us.

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)
Study#:i3321
Contact Us: For information about this clinical study, Email Us.